Charles Baum
Director/Board Member chez PMV PHARMACEUTICALS, INC.
Fortune : 188 051 $ au 31/03/2024
Postes actifs de Charles Baum
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PMV PHARMACEUTICALS, INC. | Director/Board Member | 01/04/2021 | - |
| Independent Dir/Board Member | 01/04/2021 | - | |
| POSEIDA THERAPEUTICS, INC. | Director/Board Member | 16/05/2022 | - |
| Independent Dir/Board Member | 16/05/2022 | - | |
| ACRIVON THERAPEUTICS, INC. | Director/Board Member | 22/06/2023 | - |
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Chairman | 06/11/2020 | - |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Director/Board Member | - | - |
Terremoto Biosciences, Inc.
 Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Director/Board Member | - | - |
Historique de carrière de Charles Baum
Anciens postes connus de Charles Baum
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MIRATI THERAPEUTICS | Director/Board Member | 12/11/2012 | 23/01/2024 |
| Chief Executive Officer | 07/08/2023 | 23/01/2024 | |
| Chief Tech/Sci/R&D Officer | 20/09/2021 | 23/01/2024 | |
| President | 12/11/2012 | 23/01/2024 | |
| TANGO THERAPEUTICS, INC. | Director/Board Member | 30/07/2020 | 01/01/2021 |
| Independent Dir/Board Member | 30/07/2020 | 01/01/2021 | |
| IMMUNOMEDICS, INC. | Director/Board Member | 23/02/2019 | 23/10/2020 |
| Independent Dir/Board Member | 23/02/2019 | 23/10/2020 | |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Charles Baum
| Washington University School of Medicine | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 13 |
Opérationnelle
| Director/Board Member | 9 |
| Independent Dir/Board Member | 5 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 8 |
| Technology Services | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| PMV PHARMACEUTICALS, INC. | Commercial Services |
| POSEIDA THERAPEUTICS, INC. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Technology Services |
Odyssey Therapeutics, Inc.
Odyssey Therapeutics, Inc. Packaged SoftwareTechnology Services Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation. | Technology Services |
BCTG Acquisition Corp.
 BCTG Acquisition Corp. Financial ConglomeratesFinance BCTG Acquisition Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in May 2020 and is headquartered in San Diego, CA. | Finance |
Terremoto Biosciences, Inc.
Terremoto Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Terremoto Biosciences, Inc. is a drug discovery and development company that creates highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy to deliver superior therapeutic benefit to patients. The company is based in San Francisco, CA. Terremoto is supported by leading investors, including OrbiMed, Third Rock Ventures, EcoR1 Capital, Novo Holdings, and Cormorant Capital. The company aims to expand the universe of drug targets and improve existing medicines by unleashing the power of covalent chemistry. Terremoto was founded by Peter A. Thompson and Matthew P. Jacobson, and Peter A. Thompson has been the CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Charles Baum
- Expérience
